

ESCCA 2022

WEDNESDAY 21 SEPTEMBER 2022

09.00-12.30 Training course 2: Measurable residual disease in MM

Measurable residual disease (MRD) detection during follow-up is one of the aspects currently drawing more attention in multiple myeloma (MM). Growing evidence is being gathered that confirms the clinical relevance of MRD detection, particularly for the most recent high-sensitive methodologies, as they continue to move closer to the routine clinical laboratory. In this course we will review the utility of MRD detection in clinical practice and, deepen our understanding on the Next Generation Flow methodology by gaining first-hand practical experience on data analysis, interpretation and reporting.

Level: Advanced

Organiser: Juan A. Flores-Montero (Salamanca, ES)

09.00-09.45	Measurable disease monitoring in MM: what clinicians need to know that cytometrists can answer	Noemí Puig Morón (Salamanca, ES)
09.45-10.30	Methodological considerations of MRD detection in MM by flow cytometry	Juan Flores-Montero (Salamanca, ES)
10.30-11.00	Coffee break	
11.00-12.30	Live practice session: Next Generation Flow data analysis, interpretation and reporting	Juan Flores-Montero (Salamanca, ES)

The supporting materials for the practical session have been kindly provided by Cytognos SL. The Scientific and Organising Committees have determined the content of this course and warrant its scientific independence.

Lunch on your own

14.00

Start ESCCA Conference